October 2025 Solstice Advanced Materials completed its spin-off from Honeywell and began operating as an independent publicly traded specialty materials company, creating a standalone platform that includes Solstice low-global-warming-potential propellant technologies for aerosol and healthcare applications.
September 2025 Chiesi Group completed the clinical development program for its carbon-minimal pressurized metered-dose inhalers using HFA-152a, a next-generation low-global-warming-potential aerosol propellant, and advanced the program toward regulatory submissions.
May 2025 Lupin entered a collaboration with Honeywell's advanced materials business to use Solstice Air HFO-1234ze cGMP propellant in next-generation pressurized metered-dose inhalers for asthma and COPD, with Lupin planning large-scale adoption of the low-GWP propellant in India.